Race raises full $29.7 million in heavily oversubscribed Share Purchase Plan
Race raises full $29.7 million in heavily oversubscribed Share Purchase Plan
21 December 2021 – Race Oncology Limited (“Race”) is pleased to announce that its Share Purchase Plan (SPP) has closed heavily oversubscribed with $43.9m received in applications from 2,340 shareholders. In line with the...
Race Oncology – The tip of the spear in the race to beat cancer
Race Oncology – The tip of the spear in the race to beat cancer
Race Oncology CEO/MD Phil Lynch speaks to Matt Birney of the Bulls n’ Bears Report about Race’s latest results and outlook....
Race Extends Heart Protection Collaboration with University of Newcastle
Race Extends Heart Protection Collaboration with University of Newcastle
10 December 2021 – Race Oncology Limited (“Race”) is pleased to announce it has extended and expanded its collaborative cardio-protective research program for Zantrene® (bisantrene dihydrochloride) with eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov...
Expanded Heart Protection Discovery for Zantrene
Expanded Heart Protection Discovery for Zantrene
08 December 2021 – Race Oncology Limited (“Race”) is pleased to share additional interim results from the Zantrene® (bisantrene dihydrochloride) preclinical heart safety research program led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov...
Race Oncology Investor Presentation November 2021
Race Oncology Share Purchase Plan Explained
Race Oncology AGM 2021 Presentation with Share Purchase Program Details
Race Oncology reveals breakthrough chemotherapy heart protection discovery for Zantrene
Race Announces Presentation of Preclinical Breast Cancer Zantrene Study at the 2021 Hunter Cancer Research Symposium
Race Announces Presentation of Preclinical Breast Cancer Zantrene Study at the 2021 Hunter Cancer Research Symposium
5 November 2021– Race Oncology Limited (“Race”) congratulates Dr Joshua Brzozowski from the laboratory of Associate Professor Nikki Verrills, University of Newcastle, for winning the Best Poster Prize in the Biomarkers and Targeted Therapy...
Race Commences Phase 1b/2 AML Trial at Chaim Sheba Israel
Race Commences Phase 1b/2 AML Trial at Chaim Sheba Israel
22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed an agreement with The Sheba Fund for Health Services and Research, Chaim Sheba Medical Center to commence a Phase...
